Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...

Investment analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for Protagonist Therapeutics in a report released on Monday, February 24th. HC Wainwright analyst D. Tsao now ...

H.C. Wainwright lowered the firm’s price target on Harmony Biosciences (HRMY) to $70 from $75 and keeps a Buy rating on the shares following ...

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Today, Benzinga's options scanner spotted 8 options trades for Riot Platforms. This isn't normal. The overall sentiment of ...

Minerva Neurosciences Inc (NERV) is expected to report for 4Q. NeuroMetrix Inc (NURO) is expected to report for 4Q. Nikola Corp (NKLAQ) is expected to report for 4Q. Norwegian Cruise Line Holdings Ltd ...

CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, ...

Atabak Mokari; Chief Financial Officer, Treasurer; Corcept Therapeutics Inc. Gary Robb; Chief Business Officer, Secretary; Corcept Therapeutics Inc. Joseph Belanoff; ...

Q4 2024 Earnings Conference Call February 27, 2025 11:00 AM ETCompany ParticipantsMark Chalmers - President and ...